Longevity

SS-31 (Elamipretide)

Rx · Prescription onlyInjected under the skin

SS-31

Elamipretide

Studied in mitochondrial disease.

Your plan

$209/mo, $1,254 billed once for 6 months/mo

$1,254 billed once for 6 months · unused months refunded on a medical stop

No membership fee · this is the full price · free shipping · avg 4-week supply

Get started
  • Medication, clinician care and dose adjustments, all in one price.
  • ~28-day supply. Your clinician sets your exact dose, so yours may vary; your refill arrives as you finish the last one.

A licensed clinician on our care team reviews every request and prescribes only when it's clinically appropriate.

FDA status: Compounded medication, not FDA-approved.

What it's for

Who it's for

Adults interested in the newest mitochondrial peptide.

How it's different

The only peptide here that has been through clinical trials for mitochondrial disease, at much higher doses than this.

How it works

SS-31 (elamipretide) is a short peptide that crosses the mitochondrial membranes and binds to cardiolipin, a lipid critical for ATP (cellular energy) production. By supporting mitochondrial electron transport, SS-31 enhances energy generation within cells. It is being studied in mitochondrial myopathies and cardiomyopathy. Off-label use for generalized fatigue or recovery is emerging, though human evidence is limited.

How to use it and what arrives

1 vial · lasts 4 weeks

Your clinician sets your dose: 0.4–0.8 mg · same price at every dose

How
Injected under the skin
How often
5 days a week
When
In the morning

Good to know

Redness and a firm bump at the injection site were the most common effect in trials. Rotate sites.

What the research shows

Elamipretide, a tetrapeptide that acts on mitochondria. Its only FDA approval (2025) is accelerated, for one ultra-rare disease, Barth syndrome. Its larger mitochondrial-myopathy trial missed its primary endpoints.

  1. Barth syndrome

    accelerated approval

    FDA granted accelerated approval on 19 September 2025 for muscle strength in Barth syndrome, in people weighing at least 30 kg. The approval rests on knee-extensor strength, and a confirmatory randomised trial is required.

    FDA press announcement, Forzinity (elamipretide), 19 Sept 2025; Shirley, Drugs 2026
  2. Mitochondrial myopathy

    missed primary endpoints

    In MMPOWER-3 (218 adults, 24 weeks, 40 mg daily under the skin), the six-minute walk difference from placebo was -3.2 m (p = 0.69) and the fatigue score difference was -0.07 (p = 0.37).

    Karaa et al., Neurology 2023 (MMPOWER-3)
  3. Other uses

    no approval

    No approval exists for aging, general fatigue, muscle or heart use. Animal and cell work in heart failure and other models is not proof of benefit in people.

    Tung et al., International Journal of Molecular Sciences 2025

The approval rests on a strength measure in a small trial in one rare disease, so FDA required a confirmatory trial. The approved product is not the research vial sold here.

What this does not say

  • The approval is for one rare disease in people weighing at least 30 kg; it does not establish benefit elsewhere.
  • MMPOWER-3 did not show benefit in primary mitochondrial myopathy.
  • Long-term safety outside trials is not known.

Sources

  1. SS-31 (elamipretide): a mitochondrial-targeting peptide for cardiac and mitochondrial disease. Circulation, 2016
  2. Cardiolipin and the inner mitochondrial membrane: mechanisms of cardiolipin-induced cellular stress. Biochim Biophys Acta, 2014
Read the full research

Safety

FDA status: Compounded medication, not FDA-approved.

Side effects and precautions

  • SS-31 is prescribed off-label based on preclinical support and early clinical experience.
  • In trials, the most common effect was redness and a firm bump at the injection site.

Get care right away

  • Stop and seek care for severe headache, chest pain, palpitations, or signs of allergic reaction.

When it isn't prescribed

  • SS-31 is not prescribed during pregnancy or breastfeeding, or with severe cardiac arrhythmias without careful discussion—it works on mitochondria in all tissues, including heart.

Tell your clinician about every medication, supplement, and any history of heart disease or arrhythmias.

Questions

Who might benefit from SS-31?

People with chronic fatigue, muscle weakness, or poor recovery from exercise, whose fatigue appears linked to mitochondrial or energy metabolism issues. Your clinician reviews your history and may order bloodwork to assess cellular energy markers before starting.

Can I use SS-31 with other medications?

Tell your clinician about all medications, especially cardiac or arrhythmia drugs. SS-31 works at the mitochondrial level, so heart medications need careful review. Most combinations are compatible, but timing or dose adjustments may be needed.

Still have a question? Message our team

Ready to start with SS-31?

$209/mo · $1,254 billed once for 6 months

Get started
  • Free shipping on every order
  • No membership fee
  • Same price at every dose
  • HSA and FSA accepted

More options in this area